Compare Organon & Co. Common Stock (OGN) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ross Stores, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ross Stores, Inc. trades at $230.5 (market cap $72.09B). The key difference: Ross Stores, Inc. is far larger — about 19.9× Organon & Co. Common Stock's market cap, and Ross Stores, Inc. pays the higher dividend (0.79%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ross Stores, Inc. for 48 Days on average.
| OGN | ROST | |
|---|---|---|
Market Cap | $3.62B | $72.09B |
Volume | 2,892,999 | 1,593,708 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $255.23 |
52-Week Low | $5.70 | $155.21 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $11.04B | $72.55B |
Dividend Yield | 0.58% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Ross Stores (ROST) trades at $230.57, up 2.09% today, showing strong momentum with three consecutive earnings beats. The stock faces technical headwinds with a bearish signal but maintains robust fundamentals including 42.63% ROE and 10.85% net margins. Recent news highlights store expansion initiatives and strong closeout supply positioning the company to capture value-conscious consumer demand.
ROST presents a compelling investment case with analyst consensus target of $274.14 (19% upside) and strong institutional support. However, near-term technical weakness and competitive pressures in discount retail require monitoring. The company's consistent earnings outperformance and expanding margins support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
